Simultaneous Effect of Resveratrol and Probiotics on Insulin Resistance and Glucagon-Like Peptide (GLP-1) Levels in Diabetic Rats
BACKGROUND AND OBJECTIVE: The main and effective treatment for diabetes is the use of insulin and synthetic drugs and herbal medicines, which may be accompanied by several side effects. Given that GLP-1 secretion is reduced in diabetic patients compared to healthy individuals, the aim of this study...
Guardado en:
Autores principales: | A Pegah, I Khodadadi, F Mirzaei, H Tayebinia, E Abbasi |
---|---|
Formato: | article |
Lenguaje: | EN FA |
Publicado: |
Babol University of Medical Sciences
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/44a91cc8f7b84df4a1b1db05ae910d61 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus
por: Marina Vladimirovna Shestakova
Publicado: (2010) -
The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
por: Enrique Z. Fisman, et al.
Publicado: (2021) -
Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
por: Gagik R. Galstyan, et al.
Publicado: (2017) -
Nephroprotective potential of glucagon-like peptide-1 receptor agonists
por: Minara S. Shamkhalova, et al.
Publicado: (2020) -
Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes
por: Nina A. Petunina, et al.
Publicado: (2018)